Armata Pharmaceuticals, Inc.
Business
Armata Pharmaceuticals is a late clinical-stage biotechnology company developing pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. The company's lead candidates are AP-SA02 for Staphylococcus aureus bacteremia (completed Phase 2a) and AP-PA02 for Pseudomonas aeruginosa respiratory infections in cystic fibrosis and non-cystic fibrosis bronchiectasis (completed Phase 2). Armata maintains proprietary capabilities in phage discovery, engineering, and cGMP manufacturing from bench to clinic, with a manufacturing facility in Los Angeles supporting clinical development and future commercialization.
Summary from 10-K filed 2026-03-25
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Grant and award revenue | 5 | 5 | 5 | 6 | 4 | |
| Research and development | 24 | 34 | 34 | 35 | 20 | |
| General and administrative | 12 | 13 | 12 | 7 | 8 | |
| Impairment expense | 5 | — | — | — | — | |
| Total operating expenses | 42 | 48 | 45 | 42 | 28 | |
| Operating loss | −37 | −42 | −41 | −37 | −24 | |
| Interest income | 388,000 | 697,000 | 179,000 | — | — | |
| Interest expense | −17 | −11 | −3 | — | — | |
| Change in fair value of the Convertible Loan | −121 | 31 | −22 | — | — | |
| Gain on debt and the Convertible Loan extinguishments | — | 2 | −4 | — | — | |
| Total other income (expense), net | −137 | 24 | −28 | 29,000 | 667,000 | |
| Net loss | −174 | −19 | −69 | −37 | −23 | |
| Net loss per share, basic | −4.8 | −0.52 | −1.91 | −1.08 | −0.96 | |
| Weighted average shares outstanding, basic | 36 | 36 | 36 | 34 | 24 | |
| Net loss per share, diluted | −4.8 | −0.89 | −1.91 | −1.08 | −0.96 | |
| Weighted average shares outstanding, diluted | 36 | 59 | 36 | 34 | 24 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2022 2022-11-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 9 | 9 | 14 | 15 | — | |
| Prepaid expenses and other current assets | 2 | 1 | 2 | 4 | — | |
| Other receivables | 472,000 | 744,000 | 3 | 9 | — | |
| Total current assets | 11 | 11 | 19 | 27 | — | |
| Restricted cash | 5 | 5 | 6 | 6 | — | |
| Property and equipment, net | 12 | 13 | 13 | 4 | — | |
| Operating lease right-of-use asset | 34 | 42 | 45 | 43 | 34 | |
| In-process research and development | 10 | 10 | 10 | 10 | — | |
| Goodwill | 3 | 3 | 3 | 3 | — | |
| Other assets | 973,000 | 975,000 | 2 | 2 | — | |
| Total assets | 77 | 86 | 98 | 96 | — | |
| Accounts payable and accrued liabilities | 2 | 2 | 6 | 6 | — | |
| Accrued compensation | 2 | 2 | 768,000 | 2 | — | |
| Term debt, current | — | 39 | — | — | — | |
| Current portion of operating lease liabilities | 5 | 4 | 9 | 17 | — | |
| Other current liabilities | 487,000 | 529,000 | 523,000 | — | — | |
| Total current liabilities | 9 | 48 | 16 | 25 | — | |
| Convertible Loan, non-current | 154 | 33 | 59 | — | — | |
| Term debt, non-current | 103 | 23 | 24 | — | — | |
| Operating lease liabilities, net of current portion | 27 | 28 | 29 | 32 | — | |
| Deferred tax liability | 3 | 3 | 3 | 3 | — | |
| Total liabilities | 295 | 134 | 130 | 60 | — | |
| Commitments and contingencies (Note 12) | — | — | — | — | — | |
| Common Stock, $0.01 par value; 217,000,000 shares authorized; 36,431,444 and 36,183,067 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 364,000 | 362,000 | 361,000 | 361,000 | — | |
| Additional paid-in capital | 283 | 279 | 276 | 275 | — | |
| Accumulated deficit | −502 | −328 | −309 | −240 | — | |
| Total stockholders' deficit | −219 | −48 | −32 | 36 | — | |
| Total liabilities and stockholders' deficit | 77 | 86 | 98 | 96 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −174 | −19 | −69 | −37 | −23 | |
| Depreciation expense | 2 | 1 | — | 900,000 | 1 | |
| Stock-based compensation expense | 3 | 3 | 938,000 | 3 | 3 | |
| Change in fair value of the Convertible Loan | 121 | −31 | 22 | — | — | |
| Non-cash interest expense | 17 | 11 | 3 | — | 60,000 | |
| Change in right-of-use asset | 2 | 2 | 1 | — | — | |
| Prepaid expenses and other assets | 39,000 | 5 | 5 | −8 | −2 | |
| Accounts payable and accrued liabilities | −334,000 | −4 | 39,000 | 4 | 184,000 | |
| Accrued compensation | −89,000 | 2 | −1 | 793,000 | 472,000 | |
| Operating lease liability | −1 | −5 | −13 | 4 | 499,000 | |
| Net cash used in operating activities | −26 | −38 | −47 | −32 | −24 | |
| Purchases of property and equipment | −542,000 | −2 | −8 | −2 | −1 | |
| Net cash used in investing activities | −542,000 | −2 | −8 | −2 | −1 | |
| Proceeds from issuance of term debt, net of issuance costs | 25 | 35 | 25 | — | — | |
| Payments for taxes related to net share settlement of equity awards | −46,000 | −61,000 | −43,000 | — | — | |
| Proceeds from exercise of stock options | 658,000 | 130,000 | 5,000 | 125,000 | 613,000 | |
| Net cash provided by financing activities | 26 | 35 | 54 | 44 | 26 | |
| Net change in cash, cash equivalents and restricted cash | −693,000 | −4 | −2 | 9 | 639,000 | |
| Right-of-use asset obtained by assuming operating lease liabilities | — | 977,000 | 3 | 9 | 26 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Armata Pharmaceuticals, Inc.'s CIK number?
Armata Pharmaceuticals, Inc.'s SEC CIK number is 0000921114 (921114). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Armata Pharmaceuticals, Inc.'s SEC filings?
All of Armata Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Armata Pharmaceuticals, Inc. last report earnings?
Armata Pharmaceuticals, Inc. (ARMP) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-060299). This is Armata Pharmaceuticals, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Armata Pharmaceuticals, Inc.'s most recent earnings 8-K?
Armata Pharmaceuticals, Inc.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001104659-26-060299. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Armata Pharmaceuticals, Inc.'s latest earnings 8-K →
Look up any company's CIK number →